

CURRICULUM VITAE

MONICA MONTOPOLI

Name and surname: Monica Montopoli

Place and date of birth: Venezia, 06.02.1974

Nationality: Italian

Work address: Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Largo E. Meneghetti 2, 35131 Padova, Italy

Telephone number (work): +39 049 8275090

Fax number (work): +39 049 8275093

E-mail address: monica.montopoli@unipd.it

EDUCATION AND PROFESSIONAL EXPERIENCE

2019-present: Associate professor of Pharmacology (BIO/14), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy.

2008-2019: Assistant professor of Pharmacology (BIO/14), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy.

2008: Postdoctoral fellowship, Department of Pharmacology and Anaesthesiology, University of Padova, "Sostanze di origine naturale per la sintesi di nuovi farmaci: attività farmacologica e approccio analitico multivariato per nuove strategie terapeutiche nella cura del cancro". Prof. E. Ragazzi.

2007: Postdoctoral fellowship, "Planning and performance of experiments on stress and rescue", Telethon Grant GGP06233 "Pathogenic mechanisms for degeneration of retinal ganglion cells in mitochondrial optic neuropathies".

2007: Ph.D. in "Molecular and Cellular Pharmacology", international collaboration between University of Padova, Leopold-Franzens Universität, Innsbruck, and Albert-Ludwigs Universität, Freiburg.

Doctoral dissertation "Effect of natural and semisynthetic phenols and nuclear magnetic resonance approach in human ovarian cancer cell lines".

2003: Degree in Chimica e Tecnologia Farmaceutiche, Facoltà di Farmacia, University of Padova. "Studies on U2OS cancer cell lines wt and resistant on CDDP: natural phenol compounds activity and 1H-NMR analysis".

CURRENT RESEARCH INTERESTS

Cellular and molecular pharmacology

1) Metabolomic profile and mitochondrial function of tumor cells: mechanisms of anti-cancer drugs action/toxicity and resistance.

2) Chemoprevention strategies and cell cycle-protein regulators (cyclin, CDKs, etc.), apoptosis, transcription factors (NF-kB, b-catenin).

3) Oxidative stress-mediated injury in cell models of neurodegenerative/genetic disorders and pharmacological rescue.

RESEARCH GRANTS

2020

PI contract: "Experimental study on the preventive effect of Antivirus formula derived from approved biocide (that complies to PT2 type BPR standard) MICRO OXigerm, already tested successfully from BSL-4 Lab. by UNIMI_SACCO, against infection by SARS-CoV-2 virus", WOW Kemical, Italy

2019

PI contract: "Formulazione a base di ATP nel ripristino dell'integrità di barriera enterica sottoposta a trattamento ripetuto con NSAID's", Labomar, Italy

PI contract: "Sviluppo di estratti naturali per il trattamento dell'invecchiamento cutaneo", Bottega Organica, Italy

PI contract: "In vitro studies of certain compounds for anti-senescence activity, including dextromethadone and other NMDAR antagonists, psilocin and other 5-HT2A agonists, and their derivatives", MGGM, USA

PI contract: "Anti-inflammatory activity of Enterokind Junior", Schwabe Pharma, Italy

2018

PI project PRID: "Molecular mechanisms involved in musculoskeletal disorders in oncological patients treated with tamoxifen to develop promising treatment to prevent disability and improve quality of life"

PI contract: "Pharmacological activity of d-methadone in cybrid cells model", Relmada, USA

PI contract: "Anti-inflammatory activity of Prostaplant", Schwabe Pharma, Italy

2017

PI contract: "Studi di effetti di Bifloxen sul mantenimento della barriera epiteliale intestinale", Lemnia, Italy

PI contract: "Studio sperimentale degli effetti di Colikind gocce sulla modulazione della produzione di citochine in un modello di epitelio intestinale", Schwabe Pharma, Italy

PI: Accordo Quadro con le aziende CEBIS International SAGL e Audit & Governance GmbH

2016

PI contract: "Studi di inibizione della senescenza dell'estratto di S. Haenkei", IBSA Institut Biochimique, Switzerland

PI contract: "Attività di Colikind in un modello *in vitro* di epitelio intestinale", Loacker Remedia, Italy

PI contract: "Studio di attività farmacologica di prodotti naturali in modelli di infiammazione intestinale e bronchiale", Università degli Studi di Siena, Italy

2015

PI, Contributo liberale di Ricerca "Travel Forum di Lugano", IBSA Institut Biochimique, Switzerland

2013

PI contract: "Attività antiossidante e anti-infiammatoria di estratti di curcuma in un modello cellulare di epitelio intestinale". Ecobase GmbH, Austria

2012

PI, PRAT: "Study of cisplatin resistance using transmitochondrial hybrids of cancer cells"

PI, MURST: "Riprogrammazione metabolica in modelli cellulari di patologia: identificazione di target farmacologici"

2011

PI, MURST: "Stress ossidativo e riprogrammazione metabolica: identificazione di target farmacologici"

PI, Contributo di Liberalità: Studio dell'attività di sostanze di origine naturale in modelli sperimentali di patologie degenerative e infiammatorie, per individuare composti utili a prevenire e/o rallentare il danno cellulare indotto dallo stress ossidativo. EOS, Italy

2010

PI, MURST: "Attività farmacologica di fenoli di origine naturale e di sintesi in modelli cellulari di stress ossidativo"

COLLABORATIONS IN RESEARCH FUNDED GRANTS

2019

Collaborator, AIRC IG "Development of combination of pro-senescence and senolytic compounds for prostate cancer therapy" (PI: Prof. A. Alimonti)

Collaborator, PRIN 2017 "Role of nutrients in the epigenetic control of prostate cancer progression" (PI: Prof. P. Chiarugi)

2018

Collaborator, "Development of gerosuppressant and senolytic compounds for the treatment of aging and aging-related disorders" (PI: Prof. A. Alimonti)

Collaborator, Stars Grant, University of Padova, project entitled: "Featuring a new class of interface regulators: the mitochondria-ER Spacers", Acronym: FIRMESs (PI: Dr. M. Giacomello)

2015

Collaborator, PRAT, University of Padova, project entitled "Search for natural molecules to counteract cancer metabolic reprogramming" (PI Prof. M. Carrara)

2014

Collaborator, Young Grant on Pediatric Research, "The neuronal role of lipids: from molecular function of genes to identification of biomarker in juvenile spastic paraplegia forms"

2012

Collaborator, Grant of The United Mitochondrial Disease Foundation, USA: "Estrogen mediated regulation of mitochondrial biogenesis and functions: possible therapeutic implications for Leber's Hereditary Optic Neuropathy"

Collaborator, PRAT, University of Padova, PI: Prof. L. Caparrotta, "Stress ossidativo e riprogrammazione metabolica: nuovi target farmacologici in modelli cellulari di patologia"

2008-09

Collaborator, MURST: "Sistema cardiovascolare: studio di molecole di origine naturale e di sintesi" PI: Prof. L. Caparrotta

2006-09

Collaborator, TELETHON - Grant GGP06233: "Pathogenic mechanisms for degeneration of retinal ganglion cells in mitochondrial optic neuropathies." Planning and performance of experiments on stress and rescue

2005-07

Collaborator, Ricerca Sanitaria Finalizzata Regione Veneto, “Strategie di prevenzione e trattamento del danno ossidativo in modelli cellulari di malattia neurodegenerativa”

2004

Collaborator, Progetto di ricerca Padova Ricerche – Madaus: “Effetti di escina in cellule endoteliali in ipossia”

RESEARCH COLLABORATIONS

Chemotherapy resistance and cancer metabolism: Cancer Cell Unit Hutchison/MRC Research Centre, Cambridge, UK - IOR/IOSI, Bellinzona, Switzerland - Beth Israel Deaconess Medical Center and Harvard Medical School, USA - Department of Chemical Sciences and Department of Biomedical Sciences, University of Padova, Italy

Pharmacological targets in neurological diseases: IRCCS “E. Medea”, La nostra Famiglia, Conegliano (TV) - Istituto Italiano di Tecnologia (IIT), Genova - Department of Neurological Sciences, University of Bologna - Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome

TEACHING

2018-present: “Pharmacology”, Fisioterapia (Padova, Conegliano), University of Padova

2017-present: “Pharmacology”, Scienze Infermieristiche (Treviso), University of Padova

Director of Corso di alta formazione in Fitoterapia clinica, University of Padova

2014-present: “Pharmacology”, Fisioterapia (Venice), University of Padova

Professor in Master of Fitoterapia, University of Siena

2013-present: “Preclinical and clinical studies of new drugs”, Chimica e Tecnologia Farmaceutiche, University of Padova

2010-2014: “Experimental Pharmacology”, Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2008-2010: “Methods in Pharmacology and Toxicology”, Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2007-2008: Laboratory assistance in “Methods in Pharmacology”, CLS in Pharmaceutical Biotechnology, Faculty of Pharmacy, University of Padova

2004-2006: Tutor Junior, Faculty of Pharmacy, University of Padova

MENTORING AND RESEARCH TRAINING

Post-doc supervisor:

- Supervisor of Dr. Daniela Catanzaro, post-doctoral fellow, Pharmaceutical and Pharmacological Sciences, University of Padova, Padova (03/2013-04/2014)

- Co-supervisor of Daniela Catanzaro, post-doctoral fellow, Pharmaceutical and Pharmacological Sciences, University of Padova, Padova (04/2014-03/2016), PI: E. Ragazzi, “Lipidomic/metabolomic approach to molecular mechanisms of platinum resistance in cancer cells”

- Supervisor of Dr. Veronica Cocetta, post-doctoral fellow, Pharmaceutical and Pharmacological Sciences, University of Padova, Padova (since 02/2020)

PhD student supervisor:

- Supervisor of Tatiana Trevisan (XXVIII cycle, 2013-2016), Caterina Vianello (XXIX cycle, 2014-2017), Aldo Montagna (XXIX cycle, 2014-2017), Veronica Cocetta (XXXII cycle, 2016-2019), Federico Gianfanti (XXXV cycle, 2019-in course) Doctoral school in "Pharmacological Sciences"

Final dissertation degree supervisor:

2004-2011: co-tutor of 18 students; 2011-present: tutor of 20 students

SCIENTIFIC COMMITTEES AND ORGANIZATION

2019

- **VIII° International SYRP: S.I.Fit. Young Researchers Project "Experimental models for the study of natural products"**, Imola, 14 January 2019, Scientific Committee and moderator

- **Metabolism Meets Function 2019**, A journey into the functional significance of the cellular metabolic programs, Torino, 19 July 2019, Molecular Biotechnology Center; University of Torino, Scientific Committee and organization

2018

- **Pharmacological insights of altered lipid metabolism in oncological, neurological, cardiovascular, and hepatic diseases**, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 5 December 2018, Scientific Committee and organization

- **Metabolism Meets Function 2018**, A journey into the functional significance of the cellular metabolic programs, Bari, 19-20 July 2018, Scientific Committee and organization

2017

- **V° International SYRP: S.I.Fit. Young Researchers Project**, San Marino, 20 November 2017, Scientific Committee and organization

- **ISCaM 2017 - 4th Annual Meeting - Cancer Metabolism**, 19-2 October 2017, Scientific Board

- **International Meeting "Recent advances in cancer therapy"**, Palazzo del Bo, University of Padova, 10 October 2017, Scientific Committee and organization

- **International Workshop "New pharmacological approaches in oncology"**, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 7 March 2017, Scientific Committee and organization

2016

- **International workshop "Fostering innovation Towards Start-Up"**, Department of Pharmaceutical and Pharmacological Sciences, University of Padova, in collaboration with UCL, London, 8 June 2016, Scientific Committee

- **IV° Incontro SYRP: S.I.Fit. Young Researchers Project**, Padova, 19 December 2016, Scientific Committee and organization

EDITORIAL AND RELATED ACTIVITIES

Ad hoc reviewer for journals:

Journal of Pharmacy and Pharmacology, Pharmacological Research, Journal of Ovarian Cancer, Frontiers in Oncology, Journal of Functional Foods, Cell Death & Disease, Natural Product Communications, Plos One

Membership of scientific societies:

Società Italiana di Farmacologia (SIF)

Società Italiana di Citometria (GIC)

Società Italiana di Fitoterapia (SiFit)

International Society of Cancer Metabolism (ISCaM)

PUBLICATIONS

1. Saponaro M, Giacomini I, Morandin G, Cocetta V, Ragazzi E, Carnevali I, Berretta M, Mancini M, Pagano F, **Montopoli M**. Serenoa repens and Urtica dioica fixed combination: in-vitro validation of a therapy for age-related prostatic dysfunctions, Aging. (under revision)
2. Cocetta V, Cadau J, Saponaro M, Dall'Acqua S, Sut S, Catanzaro D, Miolo G, Menilli L, Pagetta A, Ragazzi E, **Montopoli M**. Salvia haenkei as an innovative strategy to counteract skin photo-aging and restore the barrier integrity. Aging. (under revision)
3. **Montopoli M**, Zumerle S, Ruggie M, Alimonti A. Genetic and hormonal influence on SARS-CoV-2-infection susceptibility. Annals of Oncology (in press)
4. Zumerle S, **Montopoli M**, Ruggie M, Alimonti A. Reply to the Letter to the Editor: "Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients" by N. N Bennani and I. M. Bennani-Baiti. Annals of Oncology (in press)
5. Mancini M, Righetto M, Zumerle S, **Montopoli M**, Zattoni F. The bladder epicheck test as a non-invasive tool based on the identification of DNA methylation in bladder cancer cells in the urine: A review of published evidence. International Journal of Molecular Sciences, 2020, 21(18), pp. 1-9, 6542. Doi:10.3390/ijms21186542
6. Borgonetti V, Cocetta V, Biagi M, Carnevali I, Governa P, **Montopoli M**. Anti-inflammatory activity of a fixed combination of probiotics and herbal extract in an in vitro model of intestinal inflammation by stimulating Caco-2 cells with LPS-conditioned THP-1 cells medium. Minerva Pediatr. 2020;10.23736/S0026-4946.20.05765-5. doi:10.23736/S0026-4946.20.05765-5
7. Vianello C, Cocetta V, Caicci F, Boldrin F, **Montopoli M**, Martinuzzi A, Carelli V, Giacomello M. Interaction Between Mitochondrial DNA Variants and Mitochondria/Endoplasmic Reticulum Contact Sites: A Perspective Review. DNA Cell Biol. 2020;39(8):1431-1443. doi:10.1089/dna.2020.5614
8. **Montopoli M**, Zumerle S, Vettor R, Ruggie M, Zorzi M, Catapano CV, Carbone GM, Cavalli A, Pagano F, Ragazzi E, Prayer-Galetti T, Alimonti A. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n=4532). Ann Oncol. 2020;31(8):1040-1045. doi:10.1016/j.annonc.2020.04.479
9. Cocetta V, Ragazzi E, **Montopoli M**. Links between cancer metabolism and cisplatin resistance. Int Rev Cell Mol Biol. 2020;354:107-164. doi:10.1016/bs.ircmb.2020.01.005
10. Giacomini I, Cocetta V, Carrara M, Ragazzi E, **Montopoli M**. Plumbagin Induces Cell Cycle Arrest and Apoptosis in A431 Cisplatin-Resistant Cancer Cells. Natural Product Communications, Apr. 2020, doi:10.1177/1934578X20921627
11. Desbats MA, Giacomini I, Prayer-Galetti T, **Montopoli M**. Metabolic plasticity in chemotherapy resistance. Front Oncol. 2020 Mar 6;10:281. doi: 10.3389/fonc.2020.00281

12. Alajati A, D'Ambrosio M, Troiani M, Mosole S, Pellegrini L, Chen J, Revandkar A, Bolis M, Theurillat JP, Guccini I, Losa M, Calcinotto A, De Bernardis G, Pasquini E, D'Antuono R, Sharp A, Figueiredo I, Nava Rodrigues D, Welti J, Gil V, Yuan W, Vlajnic T, Bubendorf L, Chiorino G, Gnetti L, Torrano V, Carracedo A, Campese L, Hirabayashi S, Canato E, Pasut G, **Montopoli M**, Rüschoff JH, Wild P, Moch H, De Bono J, Alimonti A. CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. *J Clin Invest.* 2020 Apr 6. pii: 131133. doi: 10.1172/JCI131133
13. Castegna A, Gissi R, Menga A, **Montopoli M**, Favia M, Viola A, Cantone M. Pharmacological targets of metabolism in disease: opportunities from macrophages. *Pharmacol Ther.* 2020 Mar 6:107521. doi: 10.1016/j.pharmthera.2020.107521
14. Giacomini I, Ragazzi E, Pasut G, **Montopoli M**. The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance. *Int. J. Mol. Sci.* 2020, 21, 937. doi: 10.3390/ijms21030937
15. Fantin M, Garell F, Napoli B, Forgiarini A, Gumeni S, De Martin S, **Montopoli M**, Vantaggiato C, Orso, G. Flavonoids regulate lipid droplets biogenesis in drosophila melanogaster, *Natural Product Communications*, 2019, vol. 14, no. 5, pp. 1-8. doi: 10.1177/1934578X19852430
16. Cocetta V, Ragazzi E, **Montopoli M**. Mitochondrial Involvement in Cisplatin Resistance. *Int J Mol Sci.* 2019 Jul 10;20(14). pii: E3384. doi: c
17. Borgonetti V, Governa P, **Montopoli M**, Biagi M. Cannabis sativa L. Constituents and Their Role in Neuroinflammation. *Current Bioactive Compounds*, (2019) 15: 147. doi: 10.2174/1573407214666180703130525
18. Cocetta V, Catanzaro D, Borgonetti V, Ragazzi E, Giron MC, Governa P, Carnevali I, Biagi M, **Montopoli M**. A fixed combination of probiotics and herbal extracts attenuates intestinal barrier dysfunction from inflammatory stress in an in vitro model using Caco-2 cells. *Recent Patents on Food, Nutrition & Agriculture* (2019) 10: 62. doi: 10.2174/2212798410666180808121328
19. Bin A, Caput V., Bistoletti M, **Montopoli M**, Colucci R, Antonioli L, De Martin S, Castagliuolo I, Orso G, Giaroni C, Debetto P, Giron MC. et al. The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine. *Purinergic Signalling* 14, 409–421 (2018). doi: 10.1007/s11302-018-9623-6
20. Governa P, Marchi M, Cocetta V, De Leo B, Saunders PTK, Catanzaro D, Miraldi E, **Montopoli M**, Biagi M. Effects of *Boswellia Serrata* Roxb. and *Curcuma longa* L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. *Pharmaceuticals* (Basel). 2018 Nov 20
21. Catanzaro D, Righetto M, Pagano F, **Montopoli M**. Anti-inflammatory activity of *Serenoa Repens* on human prostate adenocarcinoma cells. *Eur Urol Suppl*, 2018 Oct, Volume 17, Issue 10, e2516. DOI: [https://doi.org/10.1016/S1569-9056\(18\)32997-X](https://doi.org/10.1016/S1569-9056(18)32997-X)
22. Fumagalli G, Giorgi G, Vágvölgyi M, Colombo E, Christodoulou MS, Collico V, Prosperi D, Dosio F, Hunyadi A, **Montopoli M**, Hyeraci M, Silvani A, Lesma G, Via

LD, Passarella D. Heteronanoparticles by Self-Assembly of Ecdysteroid and Doxorubicin Conjugates to Overcome Cancer Resistance. ACS Med Chem Lett. 2018 Apr 17;9(5):468-471. doi: 10.1021/acsmchemlett.8b00078

23. Catanzaro D, Nicolosi S, Cocetta V, Salvalaio M, Pagetta A, Ragazzi E, **Montopoli M***, Pasut G*. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells. Oncotarget, *in press*, **co-corresponding authors*
24. Strobbe D, Caporali L, Iommarini L, Maresca A, **Montopoli M**, Martinuzzi A, Achilli A, Olivieri A, Torroni A, Carelli V, Ghelli A. Haplogroup J mitogenomes are the most sensitive to the pesticide rotenone: Relevance for human diseases. Neurobiol Dis. 2018 Feb 24. pii: S0969-9961(18)30042-1
25. Caporali L, Iommarini L, La Morgia C, Olivieri A, Achilli A, Maresca A, Valentino ML, Capristo M, Tagliavini F, Del Dotto V, Zanna C, Liguori R, Barboni P, Carbonelli M, Cocetta V, **Montopoli M**, Martinuzzi A, Cenacchi G, De Michele G, Testa F, Nesti A, Simonelli F, Porcelli AM, Torroni A, Carelli V. Peculiar combinations of individually non-pathogenic missense mitochondrial DNA variants cause low penetrance Leber's hereditary optic neuropathy. PLoS Genet. 2018 Feb 14;14(2):e1007210
26. Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Pasquini E, Alajati A, Pinton S, Losa M, Sarti M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, **Montopoli M**, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, de Bono J, Carracedo A & Alimonti A. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature genetics, Nat Genet. 2018 Feb;50(2):219-228
27. Catanzaro D, Gabbia D, Cocetta V, Biagi M, Ragazzi E, **Montopoli M***, Carrara M. Silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression. Fitoterapia. 2017 Oct 12. **corresponding author*
28. Buriani A, Fortinguerra S, Sorrenti V, Dall'Acqua S, Innocenti G, **Montopoli M**, Gabbia D, Carrara M. Human Adenocarcinoma Cell Line Sensitivity to Essential Oil Phytocomplexes from Pistacia Species: a Multivariate Approach. Molecules. 2017 Aug 11;22(8). pii: E1336. doi: 10.3390/molecules22081336
29. Caputi V, Marsilio I, Filpa V, Cerantola S, Orso G, Bistoletti M, Paccagnella N, De Martin S, **Montopoli M**, Dall'Acqua S, Crema F, Di Gangi IM, Galuppini F, Lante I, Bogianni S, Rugge M, Debetto P, Giaroni C, Giron MC. Antibiotic-induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. Br J Pharmacol. 2017 Oct;174(20):3623-3639. doi: 10.1111/bph.13965. Epub 2017 Aug 30
30. Matic I, Revandkar A, Chen J, Bisio A, Dall'Acqua S, Cocetta V, Brun P, Mancino G, Milanese M, Mattei M, **Montopoli M**, Alimonti A. Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay. Aging (Albany NY). 2016 Dec 1;8(12):3223-3240. doi: 10.18632/aging.101076
31. Bertin R, Chen Z, Marin R, Donati M, Feltrinelli A, **Montopoli M**, Zambon S, Manzato E, Frolidi G. Activity of myricetin and other plant-derived polyhydroxyl compounds in human LDL and human vascular endothelial cells against oxidative stress. Biomed

Pharmacother. 2016 Aug;82:472-8. doi: 10.1016/j.biopha.2016.05.019. Epub 2016 Jun 1

32. Catanzaro D, Filippini R, Vianello C, Carrara M, Ragazzi E, **Montopoli M**. Chlorogenic Acid Interaction with Cisplatin and Oxaliplatin: Studies in Cervical Carcinoma Cells. *Natural Product Communication*. (2016) 11(4): 431-568. 2014
33. Dall'Acqua S, Catanzaro D, Cocetta V, Igl N, Ragazzi E, Giron MC, Cecconello L, **Montopoli M**. Protective effects of ψ taraxasterol 3-O-myristate and arnidiol 3-O-myristate isolated from *Calendula officinalis* on epithelial intestinal barrier. *Fitoterapia*. (2016) 109:230–235. 2014
34. Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, **Montopoli M**, Masuelli L, Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. Targeting estrogen receptor β as preventive therapeutic strategy for Leber's Hereditary Optic Neuropathy. *Hum Mol Genet*. 2015 Sep 26. pii: ddv396
35. Catanzaro D, Gaude E, Orso G, Giordano C, Pisano A, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Inhibition of Glucose-6-phosphate dehydrogenase sensitizes cisplatin resistant cells to death. *Oncotarget*. 2015 Aug 17
36. Catanzaro D, Ragazzi E, Vianello C, Caparrotta L and **Montopoli M**. Effect of quercetin on cell cycle and cyclin expression in ovarian and osteosarcoma wild type and cisplatin-resistant cell lines. *Nat Prod Commun*. 2015 Aug;10(8):1365-8
37. Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, Giron MC, Carrara M, Castagliuolo I, Ragazzi E, Caparrotta L, **Montopoli M**. Attività antinfiammatoria e antiossidante di *Boswellia serrata* in un modello di epitelio intestinale *in vitro*. *Piante medicinali* (ISSN:1825-5086). 2015, 14(1): 31-2
38. Catanzaro D, Rancan S, Orso G, Dall'Acqua S, Brun P, Giron MC, Carrara M, Castagliuolo I, Ragazzi E, Caparrotta L, **Montopoli M**. *Boswellia serrata* Preserves Intestinal Epithelial Barrier from Oxidative and Inflammatory Damage. *PLoS ONE*. 2015 10(5): e0125375
39. Catanzaro D, Vianello C, Ragazzi E, Caparrotta L, **Montopoli M**. Cell cycle control by natural phenols in Cisplatin-resistant cell lines. *Natural prod comm*. 2014 9;(10):1465-1468
40. Licciardi M, Pasut G, Amato G, Scialabba C, Mero A, **Montopoli M**, Cavallaro G, Schiavon O, Giammona G. PHEA-graft-polymethacrylate supramolecular aggregates for protein oral delivery. *Eur J Pharm Biopharm*. 2013 May;84(1):21-8
41. **Montopoli M**, Bertin R, Chen Z, Bolcato J, Caparrotta L, Froidi G. Croton lechleri sap and isolated alkaloid taspine exhibit inhibition against human melanoma SK23 and colon cancer HT29 cell lines. *J Ethnopharmacol*. 2012 Oct 30
42. Nagy EM, Sitran S, **Montopoli M**, Favaro M, Marchiò L, Caparrotta L, Fregona D. Zinc(II) complexes with dithiocarbamate derivatives: Structural characterisation and biological assays on cancerous cell lines. *J Inorg Biochem*. 2012 Sep 13;117C:131-13

43. Perli E, Giordano C, Tuppen HA, **Montopoli M**, Montanari A, Orlandi M, Pisano A, Catanzaro D, Caparrotta L, Musumeci B, Autore C, Morea V, Di Micco P, Campese AF, Leopizzi M, Gallo P, Francisci S, Frontali L, Taylor RW, d'Amati G. Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy. *Hum Mol Genet.* 2012 Jan 1;21(1):85-100
44. Frolidi G, Bertin R, Dorigo P, **Montopoli M**, Caparrotta L. Endothelium-independent vasorelaxation by ticlopidine and clopidogrel in rat caudal artery. *J Pharm Pharmacol.* 2011;63:1056-62
45. **Montopoli M**, Bellanda M, Lonardoni F, Ragazzi E, Dorigo P, Frolidi G, Mammi S, Caparrotta L. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin. *Curr Cancer Drug Targets.* 2011;11:226-35
46. Giordano C, **Montopoli M**, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. *Brain.* 2011;134:220-34
47. Frolidi G, Zagotto G, Filippini R, **Montopoli M**, Dorigo P, Caparrotta L. Activity of sap from *Croton lechleri* on rat vascular and gastric smooth muscles. *Phytomedicine.* 2009;16:768-75
48. Albertin G, Guidolin D, Sorato E, Spinazzi R, Mascarin A, Oselladore B, **Montopoli M**, Antonello M, Ribatti D. Pro-angiogenic activity of Urotensin-II on different human vascular endothelial cell populations. *Regul Pept.* 2009;157:64-71
49. **Montopoli M**, Ragazzi E, Frolidi G, Caparrotta L. Cell cycle inhibition and apoptosis induced by curcumin combined with cisplatin or oxaliplatin in human ovarian carcinoma cell lines. *Cell Proliferation.* 2009;42:195-206
50. Tramentozzi E, Pagetta A, Frasson M, Brunati A, **Montopoli M**, Finotti P. Angiogenic transforming capacity of IgG purified from plasma of type 1 diabetic subjects. *Journal of Cellular and Molecular Medicine* 2009 Jul;13(7):1336-47
51. Cozza G, Gianoncelli A, **Montopoli M**, Caparrotta L, Venerando A, Meggio F, Pinna LA, Zagotto G, Moro S. Identification of novel protein kinase CK1 delta (CK1δ) inhibitors through structure-based virtual screening. *Bioorganic & Medicinal Chemistry Letters.* 2008;18:5672-5
52. Giovagnini L, Sitran S, **Montopoli M**, Caparrotta L, Corsini M, Rosani C, Zanella P, Dou QP, Fregona D. Chemical and biological profiles of novel copper (II) complexes containing S-donor ligand for the treatment of cancer. *Inorganic Chemistry.* 2008;47:6336-43
53. Frolidi G, **Montopoli M**, Zanetti M, Dorigo P, Caparrotta L. 5-HT_{1B} receptor subtype and ageing in rat resistance vessels. *Pharmacology.* 2008; 81: 70-8
54. Frolidi G, Tissi M, **Montopoli M**. Cinetica dell'alcol etilico: fattori di variabilità in relazione agli effetti benefici e tossici. *Alcologia.* 2008, 2: 55-63

55. Sala G, Trombin F, Beretta S, Tremolizzo L, Presutto P, **Montopoli M**, Fantin M, Martinuzzi A, Carelli V, Ferrarese C. Antioxidants partially restore glutamate transport defect in Leber Hereditary Optic Neuropathy cybrids. *Journal of Neuroscience Research*. 2008; 86:3331-7
56. Tramentozzi E, **Montopoli M**, Orso G, Pagetta A, Caparrotta L, Frasson M, Brunati AM, Finotti P. Stable complexes formed by Grp94 with human IgG promoting angiogenic differentiation of HUVECs by a cytokine-like mechanism. *Molecular Immunology*. 2008;45:3639-48
57. **Montopoli M**, Frolidi G, Comelli MC, Prosdocimi M, Caparrotta L. Aescin protection of human vascular endothelial cells exposed to cobalt chloride mimicked-hypoxia and inflammatory stimuli. *Planta Medica*. 2007, 73: 285-8
58. Frolidi G, Galzignato G, Zanetti M, **Montopoli M**, Dorigo P, Caparrotta L. Are prostanoids related to positive inotropism by UTP and ATP? *Pharmacology*. 2005, 73: 140-5

PROCEEDINGS

1. **Montopoli M**, Moro S, Cozza G, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Inhibition of cell cycle and apoptosis in human cervix carcinoma cell lines induced by rhein, quercetin and plumbagin and in silico designed semisynthetic analogs. *Cytometry Part A* (2008), 73A: 61
2. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi. Response to metabolic stress in cybrids obtained from patients with Leber's hereditary optic neuropathy. *Biochimica et Biophysica acta-bioenergetics* (2008). vol. 1777, pp. S85-S85
3. Frolidi G, **Montopoli M**, Ragazzi E, Gaion RM, Caparrotta L, Dorigo P. Is in vitro vasorelaxation by ticlopidine related to P2Y12 receptors? *Purinergic signalling* (2006) 2: 242
4. **Montopoli M**, Ragazzi E, Caparrotta L, Frolidi G. Ticlopidine and clopidogrel affect vascular smooth muscle cell proliferation in culture. *Purinergic signalling* (2006) 2: 217
5. **Montopoli M**, Bellanda M, Mammi S, Moro S, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Effects of natural semisynthetic and synthetic phenolics and nuclear magnetic resonance on human ovarian cancer cell lines. *Tumori* (2005), 4(4): 6

ORAL PRESENTATIONS

1. **Montopoli M (Invited speaker)** Cancer cell metabolism and new pharmacological targets in cisplatin resistance. 3° Annual meeting of the international society of cancer metabolism, ISCaM2016, Bruxelles, Belgium, 26-29 October 2016
2. Cocetta V, Carnevali I, **Montopoli M**. Colikind as promising approach to preserve barrier intestinal: studies in *in vitro* model. XXIV Congresso Nazionale di Fitoterapia, Arezzo, Italy, 28 May 2016

3. Catanzaro D, Caparrotta L, Martinuzzi A, Giordano C, Carelli V, Ragazzi E, **Montopoli M**. Genistein pharmacological activity in Leber Hereditary Optic neuropathies (LHON): study of molecular mechanism in cybrid cell models. XIV Congresso della Società Italiana di Fitochimica 2015, Padova, Italy, 10-12 June 2015
4. Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Carrara M, Giron MC, Ragazzi E, Caparrotta L, **Montopoli M**. Attività antinfiammatoria e antiossidante di *Boswellia serrata* in un modello di epitelio intestinale *in vitro*. XXIII Congresso Nazionale di Fitoterapia, Rimini, Italy, 15-17 May 2015

POSTER PRESENTATIONS

1. Cocetta V, Catanzaro D, Ragazzi E, Pasut G, **Montopoli M**. Targeting glucose-6-phosphate dehydrogenase with a combination of liposomal cisplatin and 6-amino nicotinamide as new strategy to overcome cisplatin-resistance. 39° Congresso Nazionale SIF, Firenze, 20-23 November 2019
2. Cocetta V, Vianello C, Ragazzi E, Scorrano L, Giacomello M, **Montopoli M**. Mitophagic/autophagic inhibitors as new strategy to overcome cisplatin resistance in cancer. 39° Congresso Nazionale SIF, Firenze, 20-23 November 2019
3. Giacomini I, Cocetta V, Ragazzi E, **Montopoli M**. Natural compounds as possible modulators of lipid metabolism in cisplatin resistant cancer cells. 42nd Annual Scientific Meeting of the European Lipoprotein Club (ELC), Tutzing, Germany, 9-12 September 2019
4. Cocetta V, Catanzaro D, Giacomini I, Ragazzi E, **Montopoli M**. Lipid-metabolic reprogramming in ovarian carcinoma cell lines resistant to cisplatin. 42nd Annual Scientific Meeting of the European Lipoprotein Club (ELC), Tutzing, Germany, 9-12 September 2019
5. Napoli B, Gumeni S, Forgiarini A, Fantin M, Martinuzzi A, De Martin S, **Montopoli M**, Orso G. Drosophila REEP1 modulates ER morphology and ER stress. European Drosophila Research Conference, Losanna, Switzerland, 5-8 September 2019
6. Cocetta V, Catanzaro D, Giacomini I, Ragazzi E, **Montopoli M**. Genistein as potential compound in LHON disease: study of molecular mechanism in cybrid cell models. XXVII congresso nazionale di fitoterapia, Reggio Emilia, 24-26 May 2019
7. Morandin G, Cocetta V, Giacomini I, Ragazzi E, **Montopoli M**. IDENTIFICATION OF NATURAL EXTRACTS: STUDY OF THEIR POSSIBLE ANTIOXIDANT AND ANTI-INFLAMMATORY ACTIVITY IN IN VITRO MODELS. XXVII congresso nazionale di fitoterapia, Reggio Emilia, 24-26 May 2019
8. Giacomini I, Cocetta V, Ragazzi E, **Montopoli M**. CURCUMIN AND CISPLATIN AS NEW CHEMOTHERAPEUTIC COMPOUNDS IN ORDER TO OVERCOME CISPLATIN RESISTANCE. XXVII congresso nazionale di fitoterapia, Reggio Emilia, 24-26 May 2019
9. Catanzaro D, Giacomini I, Vianello C, Ragazzi E, **Montopoli M**. Quercetin and Cisplatin combined treatment alter cell cycle and sensitize resistant cancer cell lines.

Convegno monotematico SIF - Le basi farmacologiche dei nutraceutici, Napoli, Italy, 29-30 March 2019

10. Giacomini I, Catanzaro D, Gabbia D, Cocetta V, Biagi M, Ragazzi E, **Montopoli M**, Carrara M. Silybin as a new tool to counteract doxorubicin resistance by targeting glucose uptake. Convegno monotematico SIF - Le basi farmacologiche dei nutraceutici, Napoli, Italy, 29-30 March 2019
11. Cocetta V, Cadau J, Catanzaro D, Saponaro M, Miolo G, Ragazzi E, Alimonti A, **Montopoli M**. Anti-ageing activity of *Salvia haenkei* in an in vitro epidermal model. Convegno monotematico SIF - Le basi farmacologiche dei nutraceutici, Napoli, Italy, 29-30 March 2019
12. Giacomini I, Cocetta V, Catanzaro D, Ragazzi E, Carrara M, **Montopoli M**. Natural compounds as metabolic modulators in resistant cancer cells models. VIII incontro SYRP: Experimental models for the study of natural products, Imola, 14 January 2019
13. Catanzaro D, Cocetta V, Giacomini I, Ragazzi E, **Montopoli M**. Study of quercetin chemosensitization effect in cisplatin-resistant cancer cell models. VIII incontro SYRP: Experimental models for the study of natural products, Imola, 14 January 2019
14. Catanzaro D, Cocetta V, Giacomini I, Ragazzi E, **Montopoli M**. Cybrid cell model to study the effect of estrogen-like compounds on LHON dysfunctional mitochondria. VIII incontro SYRP: Experimental models for the study of natural products, Imola, 14 January 2019
15. Cocetta V, Vianello C, **Montopoli M**, Toker A. GLUTAMINE METABOLISM IN TRIPLE-NEGATIVE BREAST CANCER AND ITS ROLE IN CISPLATIN RESISTANCE. DF/HCC Preclinical Cancer Science Symposium - Dana-Farber Cancer Institute, Boston, 31 October 2018
16. Catanzaro D, Cocetta V, Nicolosi S, Salvalaio M, Pagetta A, Ragazzi E, Pasut G, **Montopoli M**. Overcome cisplatin-resistance by targeting glucose-6-phosphate dehydrogenase with the combination of liposomal cisplatin and 6-amino nicotinamide. ISCaM2018 - 5th Annual Meeting - Metabolic Adaptations and Targets in Cancer, Bratislava, 17-20 October 2018
17. Cocetta V, Vianello C, **Montopoli M**, Toker A. Metabolic reprogramming in triple negative breast cancer cells: role of glutamine and glucose in cisplatin resistance. ISCaM2018 - 5th Annual Meeting - Metabolic Adaptations and Targets in Cancer, Bratislava, 17-20 October 2018
18. Catanzaro D, Cocetta V, Gabbia D, Carrara M, Biagi M, Ragazzi E, **Montopoli M**. Silybin chemosensitize doxorubicin-resistant cells by targeting GLUT1. Natural Compounds in Cancer Prevention and Therapy, 3rd Edition: Trends in methods and modelling, Napoli, 4-7 September 2018
19. Catanzaro D, Cocetta V, Ragazzi E, **Montopoli M**. Natural polyphenols chemosensitize cisplatin-resistant cells through cell cycle modulation. Natural Compounds in Cancer Prevention and Therapy, 3rd Edition: Trends in methods and modelling, Napoli, 4-7 September 2018

20. Cocetta V, Catanzaro D, Miolo G, Ragazzi E, Bancaro N, Biagi M, Alimonti A, **Montopoli M**. SALVIA HAENKEI EXERTS ANTI-SENESCENCE ACTIVITY IN AN IN VITRO EPIDERMAL MODEL. VI SYRP: S.I.Fit. YOUNG RESEARCHERS PROJECT, Fiuggi, 25-27 May 2018
21. Catanzaro D, Cocetta V, Gabbia D, Ragazzi E, Biagi M, Carrara M, **Montopoli M**. SILYBIN: A NATURAL COMPOUND ABLE TO OVERCOME DOXORUBICIN RESISTANCE PHENOMENA. VI SYRP: S.I.Fit. YOUNG RESEARCHERS PROJECT, Fiuggi, 25-27 May 2018
22. Cocetta V, Catanzaro D, Miolo G, Cadau J, Ragazzi E, Alimonti A, **Montopoli M**. Anti-senescence activity of Salvia Haenkei on a skin cellular model. AMWC 2018 - The 16th Anti-Aging and Aesthetic Medicine World Congress, Montecarlo, 4-7 April 2018
23. Cocetta V, Catanzaro D, Gabbia D, Ragazzi E, Biagi M, Carrara M, **Montopoli M**. SILYBIN GLYCOLYSIS INHIBITOR AS PROMISING AGENT IN CHEMOTHERAPY, VI SYRP: S.I.Fit. YOUNG RESEARCHERS PROJECT, Republic of San Marino, 20 November 2017
24. Cocetta V, Catanzaro D, Vianello C, Ragazzi E, **Montopoli M**. ROLE OF MITOCHONDRIA IN CISPLATIN-RESISTANCE PHENOMENA. 38° congresso SIF, Rimini, 25-28 October 2017
25. Cocetta V, Vianello C, Catanzaro D, Ragazzi E, Scorrano L, **Montopoli M**. IMBALANCE OF MITOCHONDRIAL "SHAPING PROTEINS" AND CISPLATIN RESISTANCE. iSCaM2017 - 4th Annual Meeting - Cancer Metabolism, Bertinoro, 19-21 October 2017
26. Cocetta V, Vianello C, Catanzaro D, Ragazzi E, **Montopoli M**. MITOCHONDRIAL ALTERATIONS INVOLVED IN CISPLATIN RESISTANCE PHENOMENA. Padua-Mit-Innsbruck "Mitochondrial Conference", Padova, 13-14 September 2017
27. Cocetta V.1, Vianello C. 1, Catanzaro D. 1, Ragazzi E. 1, **Montopoli M**. MITOCHONDRIA AS CISPLATIN TARGETS: NEW APPROACH TO COUNTERACT RESISTANCE MECHANISM. 2° Special conference EACR AACR SIC - The challenges of optimising immune and targeted therapies - from cancer biology to the clinic, Firenze, 24-27 June 2017
28. Cocetta V, Catanzaro D, Stefano Dall'Acqua S, Ragazzi E, **Montopoli M**. Cannabis Sativa modulates epithelial permeability in an in vitro intestinal inflammation model. XXV Congresso Nazionale di Fitoterapia - SYRP: S.I.FIT. YOUNG RESEARCHERS PROJECT, Arezzo, 26 May 2017
29. Vianello C, Catanzaro, Cocetta V, Ragazzi E, **Montopoli M**. Mitochondrial remodeling involved in cisplatin resistance. 19° Seminario SIF, Rimini, 20-22 September 2016
30. Catanzaro D, Gaude E, Orso G, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Carrara M, Frezza C, **Montopoli M**. Targeting Glucose-6-phosphate dehydrogenase to overcome cisplatin resistance in ovarian cancer. Translational research in cancer cell metabolism - EMBO Conference, Bilbao, 4-6 October 2016
31. Vianello C, Brown K.K, Catanzaro D, **Montopoli M**, Toker A. Highlighting glucose and glutamine metabolism in breast cancer and their role in cisplatin chemoresistance.

Translational research in cancer cell metabolism - EMBO Conference, Bilbao, 4-6 October 2016

32. Catanzaro D, Gaude E, Orso G, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Inhibition of pentose phosphate pathway as novel approach to counteract cisplatin resistance. 58th Annual Meeting of the Italian Cancer Society, Verona, 5-8 September 2016
33. Catanzaro D, Gabbia D, Cocetta V, Ragazzi E, **Montopoli M**, Carrara M. Natural polyphenols as chemosensitizer: studies in resistant cancer cells. 58th Annual Meeting of the Italian Cancer Society, Verona, 5-8 September 2016
34. Catanzaro D, Gabbia D, Cocetta V, Ragazzi E, **Montopoli M**, Carrara M. Natural polyphenols as chemosensitizer: studies in resistant cancer cells. 58th Annual Meeting of the Italian Cancer Society, Verona, 5-8 September 2016
35. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Mitochondrial network organization in cisplatin resistant cells. 37° Congresso Nazionale della Società Italiana di Farmacologia, I NUOVI ORIZZONTI DELLA RICERCA FARMACOLOGICA: TRA ETICA E SCIENZA. Napoli, 27-30 October 2015
36. Catanzaro D, Gaude E, Orso G, Guzzo G, Rasola A, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Metabolic liabilities in cisplatin cancer resistant cells. Cancer and Metabolism conference, Cambridge, UK, 28-30 September 2015
37. **Montopoli M**, Barattin M, Vianello C, Bellato F, Catanzaro D, Bersani S, Salmaso S. Anionic Liposomes for Enhanced Metformin Delivery To Cancer Cell Mitochondria. 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM, Venice, 16-19 September 2015
38. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, Caliceti P, **Montopoli M**. Cisplatin resistance and cell metabolism: ¹H-NMR approach to profile metabolites in living ovarian carcinoma cells. 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM, Venice, 16-19 September 2015
39. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Cisplatin-resistant cells exert the glycolysis dependent phenotype. 2nd ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF CANCER METABOLISM, Venice, 16-19 September 2015
40. Catanzaro D, Orso G, Giordano C, Vianello C, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Use of transmitochondrial hybrids to investigate the influence of mtDNA mutations in cisplatin resistance. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic, Firenze, 20-23 June 2015
41. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, **Montopoli M**. ¹H-NMR to detect intracellular metabolites in living human ovarian cancer cell lines. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic, Firenze, 20-23 June 2015

42. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Depletion of mitochondrial DNA modulates cellular sensitivity to cisplatin. EACR-AACR-SIC 2015 Special Conference on Anticancer Drug Action and Drug Resistance from Cancer Biology to the Clinic, Firenze, 20-23 June 2015
43. **Montopoli M**, Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Giron MC, Carrara M, Caparrotta L, Ragazzi E. Antioxidant and anti-inflammatory activities of *Boswellia serrata* in epithelial intestinal cell line. XIV Congresso della Società Italiana di Fitochimica, Padova, 2015, 10-12 June 2015
44. Catanzaro D, Orso G, Giordano C, Vianello C, Ragazzi E, Caparrotta L, Frezza C, **Montopoli M**. Transmitochondrial hybrids as model to investigate mitochondria involvement in cisplatin resistance. Translational advances in cancer cell signalling and metabolism - EMBO workshop. Bilbao, 7-9 October 2014
45. Catanzaro D, Bellanda M, Ragazzi E, Vianello C, Mammi S, Caparrotta L, **Montopoli M**. ¹H- NMR approach to fingerprint metabolic profile of human cancer cell lines. Translational advances in cancer cell signalling and metabolism - EMBO workshop. Bilbao, 7-9 October 2014
46. Vianello C, Catanzaro D, Ragazzi E, Caparrotta L, **Montopoli M**. Impairment of mitochondrial oxidative metabolism in platinating drug resistance. Translational advances in cancer cell signalling and metabolism -EMBO workshop. Bilbao,7-9 October 2014
47. Vianello C, Catanzaro D, **Montopoli M**. Mitochondrial function in human cisplatin-resistant and sensitive cell lines. Seminario Nazionale in Farmacologia e Scienze Affini per Dottorandi, Assegnisti di Ricerca, Post-dottorandi e Specializzandi, Rimini, 16-18 September 2014
48. Catanzaro D, Frezza C, Orso G, Bellanda M, Ragazzi E, Caparrotta L, **Montopoli M**. Lipogenic phenotype of ovarian carcinoma cell lines resistant to cisplatin. *Membrane, Morphology and Function. FEBS/EMBO*. Fara San Martino, Italy, 5-8 May 2014
49. Catanzaro D, Rancan S, Dall'Acqua S, Brun P, Castagliuolo I, Giron MC, Frolidi G, Ragazzi E, Caparrotta L, **Montopoli M**. *Boswellia serrata*: antioxidant and antiinflammatory activities in epithelial intestinal cells. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia*. Torino, Italy, 23-26 October 2013
50. Catanzaro D, **Montopoli M**, Bellanda M, Frezza C, Frolidi G, Ragazzi E, Caparrotta L. Rho0 cells and metabolomic approach to exploit mechanism of resistance to cisplatin in ovarian cancer cell lines. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia*, Torino, Italy, 23-26 October 2013
51. Chen Z, Bertin R, Marin R, **Montopoli M**, Frolidi G. Antioxidant properties of medicinal plants as potential antiatherosclerotic remedies: *in vitro* and *ex vivo* studies. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia*, Torino, Italy, 23-26 October 2013
52. Chen Z, Donati M, Mondin A, Bertin R, Miranda FM, **Montopoli M**, Frolidi G. *In vitro* radical scavenging activity of essential oils from Brazilian medicinal plants: *Croton zehntneri*, *Pterodon emarginatus* and *Schinopsis brasiliensis*. *XXXIV° Congresso Nazionale della Società Italiana di Farmacologia*, Torino, Italy, 23-26 October 2013

53. Catanzaro D **Montopoli M**, Bellanda M., Ragazzi E, Froidi G., Giordano C, Gaude E, Sciacovelli M, Frezza C, Caparrotta L. Insight into mitochondrial and metabolic asset of cisplatin ovarian cancer cells. *Cancer and Metabolis* 2013, Amsterdam, The Netherlands, 24-25 June 2013
54. Catanzaro D, **Montopoli M**, Bellanda M, Ragazzi E, Froidi G, Mammi S, Caparrotta L. Molecular Mechanism of resistance to cisplatin: study of metabolism in ovarian cancer cells. XI ISPCC, XI International symposium on platinum coordination compounds in cancer chemotherapy stem cells, DNA repair mechanisms, DNA-damaging agents. Verona, Italy, 11-14 October 2012
55. **Montopoli M**, Catanzaro D, Bellanda M, Giordano C, Mammi S, Ragazzi E, Caparrotta L. Metabolic profile of cisplatin-resistant phenotype: studies in ovarian carcinoma cell lines. 22nd Biennial EACR (European Association for Cancer Research) Congress. Barcelona, Spain, 7-10 July 2012
56. Martinuzzi A, **Montopoli M**, Zanarella E, Fantin M, Rossetto M, De Nardo V, Carelli V, Ghelli A, Rugolo M, Daga A, Bresolin N. Strategie di prevenzione e trattamento del danno ossidativo in modelli cellulari di malattia neurodegenerativa. "Il Veneto per la Ricerca" La ricerca sanitaria promossa e sostenuta dalla regione Veneto. Venezia, Italy, 28-29 June 2012
57. **Montopoli M**, Catanzaro D, Martinuzzi A, Pisano A, Caparrotta L, d'Amati G, Carelli V, Giordano C. Effects of genistein on Leber's hereditary optic neuropathy (LHON) mitochondrial metabolism. Euromit 8 European Meeting on Mitochondrial Pathology. Zaragoza, Spain, 20-23 June 2011
58. **Montopoli M**, Bellanda M, Ragazzi E, Catanzaro D, Froidi G, Giordano C, Mammi S, Caparrotta L. Mitochondria on cisplatin resistance: studies on ovarian cancer cells. 35° Congresso nazionale della Società Italiana di Farmacologia. Il Farmaco: dalla ricerca alla salute dell'uomo, Bologna, Italy, 14-17 September 2011
59. **Montopoli M**, Catanzaro D, Perli E, Ragazzi E, Froidi G, Giordano C, Caparrotta L. Oxidative stress and metabolic reprogramming: study of pharmacological targets in cellular models of mitochondrial disease. Il Farmaco: dalla ricerca alla salute dell'uomo, Bologna, Italy, 14-17 September 2011
60. Bertin R, **Montopoli M**, Solda L, Martanez-Vasquez M, Garca-Argaa A, Caparrotta L, Froidi G. Pharmacological properties of *Casimiroa* spp. extracts and isolated phenolic compounds: vasorelaxation and antioxidant effects. Il Farmaco: dalla ricerca alla salute dell'uomo, Bologna, Italy, 14-17 September 2011
61. Giordano C, **Montopoli M**, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Estrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. XII International Congress on Neuromuscular disease. Naples, Italy, 17-22 July 2010
62. Perli E, Giordano C, Tuppen HA, Orlandi M, Autore C, Pisano A, Musumeci B, Taylor RW, **Montopoli M**, d'Amati G. Phenotypic expression of homoplasmic mutations in mitochondrial tRNA genes: role of aminoacyl-tRNA synthetases. XII International Congress on Neuromuscular disease, Naples, Italy, 17-22 July 2010

63. **Montopoli M**, Ragazzi E, Frolidi G, Dorigo P, Caparrotta L. Curcumin increases sensitivity of resistant ovarian tumour cells to platinum drugs: apoptotic effects and cell cycle alterations. 34° Congresso Nazionale della Società Italiana di Farmacologia, Rimini, 14-17 October 2009
64. Frolidi G, **Montopoli M**, Caparrotta L, Dorigo P. Studies in vitro of pharmacological properties of ecuadorian blood-red sap from croton lechleri. 34° Congresso nazionale della Società Italiana di Farmacologia, Rimini, 14-17 October 2009
65. **Montopoli M**, Moro S, Cozza G, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. *In vitro* antitumor properties of in silico designed semisynthetic phenol derivatives. *III Meeting Nuove prospettive in chimica farmaceutica*, Ciocco Castelveccchio-Lucca, Italy, 13-14 Febbraio 2009
66. Tramentozzi E, Pagetta A, Frasson M, **Montopoli M**, Finotti P. Glucose-regulated protein94 (Grp94) forms stable complexes with human IgG that promote a strong angiogenic transformation of HUVECs by a cytokine-like mechanism. *X National Biotechnology Congress*, Perugia, Italy, 17-19 September 2008
67. Tramentozzi E, Pagetta A, Frasson M, **Montopoli M**, Finotti P. Immune complexes of Glucose-regulated protein94 (Grp94) with IgG, present in the plasma of type 1 diabetic subjects, show strong angiogenic-transforming capacity on HUVECs. *33rd FEBS Congress and 11th IUBMB Conference: Biochemistry of Cell Regulation*, Athens, Greece, 28 June-3 July 2008
68. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi A. Development of flexible paradigm of oxidative stress to investigate the pathogenesis of mtDNA mutations in the cybrid system. *Euromit, The seventh European Meeting on Mitochondrial Pathology*, Stockholm, Sweden, 11-14 June 2008
69. **Montopoli M**, Fantin M, Caparrotta L, Carelli V, Martinuzzi A. Response to metabolic stress in cybrids obtained from patients with Leber's hereditary optic neuropathy. *XV European Bioenergetic Conference*, Dublin, Ireland, 19-24 July 2008
70. **Montopoli M**, Caparrotta L, Dorigo P, Frolidi G. Croton Lechleri sap inhibits in vitro proliferation of HT-29 human colon cancer cells. *2° Verona International Meeting on Foods, Phytotherapeutic Compounds and Health*, Verona, 29-30 September 2007
71. Frolidi G, Caparrotta L, **Montopoli M**, Garcia-Argàez A, Munoz-Ocoteo V, Martinez-Vásquez M. Azione farmacologia in vitro di casamiroa edulis in tessuti vascolari a resistenza. *XVI Congresso Italo-latinoamericano di Etnomedicina "Carlo L. Spegazzini"*, La Plata, Argentina, 4-8 September 2007
72. **Montopoli M**, Moro S, Cozza G, Zagotto G, Frolidi G, Ragazzi E, Caparrotta L. Natural and semisynthetic anthraquinones, flavonoids and naphthoquinones effects on cell cycle in human ovarian cancer. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*, Cagliari, 6-9 June 2007
73. Tramentozzi E, Pagetta A, **Montopoli M**, Frasson M, Finotti P. Angiogenesis induced by "heat shock protein Glucose-regulated protein 94 (GRP94) with mechanism similar to that of a cytokine. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*, Cagliari, 6-9 June 2007

74. Frolidi G, **Montopoli M**, Dorigo P, Caparrotta L. Direct effects of ticlopidine and clopidogrel on resistance vessel in vitro. *XXXIII Congresso Nazionale della Società Italiana di Farmacologia*, Cagliari, 6-9 June 2007
75. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. Copper(II)-based potential antitumor agents with S-donor chelating ligands. *6th Symposium on Pharmaco-Bio-Metallics*, Napoli, 30 November-1 December 2006
76. **Montopoli M**. Natural and semisynthetic phenolics and nuclear magnetic resonance in human ovarian cancer cell lines. *X Seminario Nazionale Dottorandi in Farmacologia ed affini*, Pontignano-Siena, 25-28 September 2006
77. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. H-NMR reveals significantly different levels of glutathione in sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXXVI National Congress on Magnetic Resonance*, Salerno, 20-23 September 2006
78. Prosdocimi M, **Montopoli M**, Frolidi G, Comelli MC, Caparrotta L. Escina inibisce nelle cellule endoteliali umane l'effetto dell'ipossia e dell'infiammazione. *10° Congresso Nazionale del Collegio Italiano di Flebologia*, Siena, 17-20 September 2006
79. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. CU(II) and ZN(II)-based potential antitumor agents with sulfur chelating ligands. *XX Congresso Nazionale della Società Chimica Italiana*, Firenze, 10-15 September 2006
80. Giovagnini L, Sitran S, Caparrotta L, **Montopoli M**, Fregona D. Cu(II) potential antitumor agents with sulfur chelating agents. *37th International Conference on Coordination Chemistry*, Cape Town, South Africa, 13-18 August 2006
81. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. ¹H NMR reveals significantly different levels of glutathione in sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXII International Conference on Magnetic Resonance in Biological Systems*, Göttingen, Germany, 20-25 August 2006
82. Frolidi G, **Montopoli M**, Ragazzi E, Gaion RM, Caparrotta L, Dorigo P. Is in vitro vasorelaxation by ticlopidine related to P2Y₁₂ receptors? *8th International Symposium on Adenosine and Adenine Nucleotides*, Ferrara, 24-28 May 2006
83. **Montopoli M**, Ragazzi E, Caparrotta L, Frolidi G. Ticlopidine and clopidogrel affect vascular smooth muscle cell proliferation in culture. *8th International Symposium on Adenosine and Adenine nucleotides*, Ferrara, 24-28 May 2006
84. Bellanda M, **Montopoli M**, Lonardoni F, Caparrotta L, Mammi S. ¹H-NMR study of sensitive or spontaneously resistant to cisplatin cells from human ovarian cancer lines. *XXXV National Congress on Magnetic Resonance*, Monte Porzio Catone-Roma, 31 August-3 September 2005
85. **Montopoli M**, Frolidi G, Ragazzi E, Bellanda M, Mammi S, Caparrotta L. ¹H-NMR Spectroscopy and cytotoxicity of natural phenolic compounds on human wild and cisplatin resistant cancer cell. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*, Napoli, 1-4 June 2005

86. **Montopoli M**, Frolidi G, Comelli MC, Prosdocimi M, Caparrotta L. Effect of b-aescin on vascular endothelial cell exposed to cobalt chloride, a model of experimental hypoxia. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*, Napoli, 1-4 June 2005
87. Frolidi G, Franceschi A, **Montopoli M**, Ragazzi E, Gaion RM, Giron MC, Dorigo P, Caparrotta L. Actions of ticlopidine and clopidogrel on resistance vessel. *XXXII° Congresso Nazionale della Società Italiana di Farmacologia*, Napoli, 1-4 June 2005
88. **Montopoli M**, Frolidi G, Ragazzi E, Caparrotta L. Studies on wild type and CDDP resistant A431 cells lines: ¹H-NMR spectroscopy and effect of natural phenolic compounds. *VIII Seminario Nazionale Dottorandi in Farmacologia ed affini*. Pontignano-Siena, 20-23 September 2004